Ignite Creation Date:
2025-12-25 @ 2:32 AM
Ignite Modification Date:
2026-01-08 @ 1:32 PM
Study NCT ID:
NCT03705234
Status:
ACTIVE_NOT_RECRUITING
Last Update Posted:
2025-12-11
First Post:
2018-10-10
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
A Randomized Trial Assessing the Effects of Inclisiran on Clinical Outcomes Among People With Cardiovascular Disease
Sponsor:
Organization:
Raw JSON
{'hasResults': False, 'derivedSection': {'miscInfoModule': {'versionHolder': '2025-12-24'}, 'conditionBrowseModule': {'meshes': [{'id': 'D050197', 'term': 'Atherosclerosis'}], 'ancestors': [{'id': 'D001161', 'term': 'Arteriosclerosis'}, {'id': 'D001157', 'term': 'Arterial Occlusive Diseases'}, {'id': 'D014652', 'term': 'Vascular Diseases'}, {'id': 'D002318', 'term': 'Cardiovascular Diseases'}]}, 'interventionBrowseModule': {'meshes': [{'id': 'C585830', 'term': 'ALN-PCS'}, {'id': 'D000077330', 'term': 'Saline Solution'}], 'ancestors': [{'id': 'D000077324', 'term': 'Crystalloid Solutions'}, {'id': 'D007552', 'term': 'Isotonic Solutions'}, {'id': 'D012996', 'term': 'Solutions'}, {'id': 'D004364', 'term': 'Pharmaceutical Preparations'}]}}, 'protocolSection': {'designModule': {'phases': ['PHASE3'], 'studyType': 'INTERVENTIONAL', 'designInfo': {'allocation': 'RANDOMIZED', 'maskingInfo': {'masking': 'QUADRUPLE', 'whoMasked': ['PARTICIPANT', 'CARE_PROVIDER', 'INVESTIGATOR', 'OUTCOMES_ASSESSOR']}, 'primaryPurpose': 'PREVENTION', 'interventionModel': 'PARALLEL'}, 'enrollmentInfo': {'type': 'ACTUAL', 'count': 16124}}, 'statusModule': {'overallStatus': 'ACTIVE_NOT_RECRUITING', 'startDateStruct': {'date': '2018-10-30', 'type': 'ACTUAL'}, 'expandedAccessInfo': {'hasExpandedAccess': False}, 'statusVerifiedDate': '2025-12', 'completionDateStruct': {'date': '2049-12', 'type': 'ESTIMATED'}, 'lastUpdateSubmitDate': '2025-12-10', 'studyFirstSubmitDate': '2018-10-10', 'studyFirstSubmitQcDate': '2018-10-10', 'lastUpdatePostDateStruct': {'date': '2025-12-11', 'type': 'ESTIMATED'}, 'studyFirstPostDateStruct': {'date': '2018-10-15', 'type': 'ACTUAL'}, 'primaryCompletionDateStruct': {'date': '2026-10', 'type': 'ESTIMATED'}}, 'outcomesModule': {'primaryOutcomes': [{'measure': 'Number of participants with a major adverse cardiovascular event (MACE)', 'timeFrame': 'Median follow-up of 5-years', 'description': 'Defined as time to first occurrence - during the scheduled treatment period - of:\n\n* Coronary heart disease (CHD) death;\n* Myocardial infarction;\n* Fatal or non-fatal ischemic stroke; or\n* Urgent coronary revascularization procedure.'}], 'secondaryOutcomes': [{'measure': 'Number of participants with MACE among those recorded to be taking high-intensity statin at baseline', 'timeFrame': 'Median follow-up of 5-years'}, {'measure': 'Number of participants with a composite of CHD death or myocardial infarction', 'timeFrame': 'Median follow-up of 5-years'}, {'measure': 'Number of participants with cardiovascular death', 'timeFrame': 'Median follow-up of 5-years'}]}, 'oversightModule': {'oversightHasDmc': True, 'isFdaRegulatedDrug': True, 'isFdaRegulatedDevice': False}, 'conditionsModule': {'keywords': ['Inclisiran', 'PCSK9', 'Cardiovascular', 'LDL Cholesterol', 'Cholesterol', 'Lipid', 'RNA interference'], 'conditions': ['Atherosclerotic Cardiovascular Disease']}, 'referencesModule': {'references': [{'pmid': '33990512', 'type': 'DERIVED', 'citation': 'Warden BA, Duell PB. Inclisiran: A Novel Agent for Lowering Apolipoprotein B-containing Lipoproteins. J Cardiovasc Pharmacol. 2021 Aug 1;78(2):e157-e174. doi: 10.1097/FJC.0000000000001053.'}], 'seeAlsoLinks': [{'url': 'https://www.orion4trial.org', 'label': 'Study website'}]}, 'descriptionModule': {'briefSummary': 'ORION-4 is a research study coordinated by the University of Oxford and co-sponsored by The University of Oxford and Novartis (Protocol: CTSU\\_MDCO-PCS-17-01 (CKJX839B12301)). The study aims to find out if a new cholesterol-lowering injection (inclisiran) safely lowers the risk of heart attacks and strokes in people who have already had one of these conditions, or who have had an operation or procedure to treat blocked arteries.', 'detailedDescription': 'The ORION-4 study aims to provide evidence about both the efficacy and safety of inclisiran. Inclisiran is a PCKS9 synthesis inhibitor which has been found to reduce LDL-cholesterol by about 50-60%. ORION-4 will investigate the effects of inclisiran on major adverse cardiovascular events.\n\nThe study is intended to be conducted at approximately 180 clinical sites in the UK and the USA. Approximately 15,000 participants aged 40 years or older for men, and 55 years or older for women, with pre-existing atherosclerotic cardiovascular disease will be randomized between inclisiran sodium 300 mg and matching placebo (given by subcutaneous injection on the day of randomization, at 3 months and then every 6-months) in a 1:1 ratio for a planned median duration of about 5 years.'}, 'eligibilityModule': {'sex': 'ALL', 'stdAges': ['ADULT', 'OLDER_ADULT'], 'minimumAge': '40 Years', 'healthyVolunteers': False, 'eligibilityCriteria': "Inclusion Criteria\n\nHistory or evidence of at least one of the following:\n\n* Prior MI; or\n* Prior ischemic stroke; or\n* Peripheral artery disease as evident by prior lower extremity artery revascularization or aortic aneurysm repair.\n\nMinimum age is 40 years for men and 55 years for women\n\nExclusion Criteria\n\nNone of the following must be satisfied (based on self-reported medical history):\n\n* Acute coronary syndrome or stroke less than 4 weeks before the Screening visit or during the Run-in period;\n* Coronary revascularization procedure planned within the next 6 months;\n* Known chronic liver disease;\n* Current or planned renal dialysis or transplantation;\n* Previous exposure to inclisiran or participation in a randomized trial of inclisiran;\n* Previous (within about 3 months), current or planned treatment with a monoclonal antibody targeting PCSK9, or with a drug known to be contra-indicated with inclisiran (none currently known);\n* Known to be poorly compliant with clinic visits or prescribed medication;\n* Medical history that might limit the individual's ability to take trial treatments for the duration of the study (e.g. severe respiratory disease; cancer or evidence of spread within approximately the last 5 years, other than non-melanoma skin cancer; or history of alcohol or substance misuse) or may put the individual at significant risk in the opinion of the investigator (or their authorised deputy) if he/she were to participate in the trial;\n* Women of child-bearing potential, current pregnancy, or lactation;\n* Current participation in a clinical trial with an unlicensed drug or device; or\n* Staff personnel directly involved with the study and any family member of the investigational study staff."}, 'identificationModule': {'nctId': 'NCT03705234', 'acronym': 'ORION-4', 'briefTitle': 'A Randomized Trial Assessing the Effects of Inclisiran on Clinical Outcomes Among People With Cardiovascular Disease', 'organization': {'class': 'OTHER', 'fullName': 'University of Oxford'}, 'officialTitle': 'HPS-4/TIMI 65/ORION-4: A Double-blind Randomized Placebo-controlled Trial Assessing the Effects of Inclisiran on Clinical Outcomes Among People With Atherosclerotic Cardiovascular Disease', 'orgStudyIdInfo': {'id': 'CTSU_MDCO_PCS-17-01'}}, 'armsInterventionsModule': {'armGroups': [{'type': 'EXPERIMENTAL', 'label': 'Inclisiran', 'description': 'Inclisiran sodium 300 milligrams (mg) will be administered as a SC injection at randomization, 3 months and then every 6 months.', 'interventionNames': ['Drug: Inclisiran']}, {'type': 'PLACEBO_COMPARATOR', 'label': 'Placebo', 'description': 'Placebo will be administered as SC injections of saline solution at randomization, 3 months and then every 6 months.', 'interventionNames': ['Drug: Placebo']}], 'interventions': [{'name': 'Inclisiran', 'type': 'DRUG', 'description': 'Inclisiran is a small interfering ribonucleic acid (RNA) that inhibits PCSK9 synthesis.', 'armGroupLabels': ['Inclisiran']}, {'name': 'Placebo', 'type': 'DRUG', 'otherNames': ['Saline solution'], 'description': 'Placebo will be supplied as sterile normal saline (0.9% sodium chloride in water for injection).', 'armGroupLabels': ['Placebo']}]}, 'contactsLocationsModule': {'locations': [{'zip': '02115', 'city': 'Boston', 'state': 'Massachusetts', 'country': 'United States', 'facility': 'TIMI Study Group', 'geoPoint': {'lat': 42.35843, 'lon': -71.05977}}, {'zip': 'OX3 7LF', 'city': 'Oxford', 'state': 'Oxfordshire', 'country': 'United Kingdom', 'facility': 'CTSU, University of Oxford', 'geoPoint': {'lat': 51.75222, 'lon': -1.25596}}], 'overallOfficials': [{'name': 'Louise Bowman', 'role': 'PRINCIPAL_INVESTIGATOR', 'affiliation': 'University of Oxford'}, {'name': 'Marion Mafham', 'role': 'PRINCIPAL_INVESTIGATOR', 'affiliation': 'University of Oxford'}, {'name': 'David Preiss', 'role': 'PRINCIPAL_INVESTIGATOR', 'affiliation': 'University of Oxford'}, {'name': 'Martin Landray', 'role': 'PRINCIPAL_INVESTIGATOR', 'affiliation': 'University of Oxford'}]}, 'ipdSharingStatementModule': {'url': 'https://www.ndph.ox.ac.uk/data-access', 'infoTypes': ['STUDY_PROTOCOL', 'SAP'], 'timeFrame': 'After the main study results have been announced and published', 'ipdSharing': 'YES', 'description': 'Proposals for substudies must be approved by the Steering Committee. Procedure for accessing the data for this study are available on https://www.ndph.ox.ac.uk/data-access', 'accessCriteria': 'See URL'}, 'sponsorCollaboratorsModule': {'leadSponsor': {'name': 'University of Oxford', 'class': 'OTHER'}, 'collaborators': [{'name': 'The TIMI Study Group', 'class': 'OTHER'}, {'name': 'Novartis Pharmaceuticals', 'class': 'INDUSTRY'}], 'responsibleParty': {'type': 'SPONSOR'}}}}